BRAINSWAY LTD-ADR
BWAYNASDAQTrading Snapshot
- Day Range
- $13.32 – $13.59
- 52-Week Range
- $7.14 – $17.40
- Volume
- $2.54B
- Avg Volume
- $3.35B
- Shares Outstanding
- 39.2M
- Next Earnings
- Nov 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $52M
- Last Q Revenue
- $17M
- P/E Ratio
- 54.2
- P/S Ratio
- 8.1x
- EPS (TTM)
- $0.47
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −44.3%
Why Investors Own BWAY
- ✓High-growth profile — revenue up -6.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 30% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BRAINSWAY LTD-ADR
BWAY
StockOtter · stockotter.spaceAbout BRAINSWAY LTD-ADR
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Brainsway (NASDAQ:BWAY) Shares Gap Down – What’s Next?
Brainsway Ltd. Sponsored ADR (NASDAQ: BWAY - Get Free Report)'s share price gapped down prior to trading on Tuesday. The stock had previously closed at $13.57, but opened at $13.14. Brainsway shares last traded at $13.42
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™
Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity
Analyzing Brainsway (NASDAQ:BWAY) and Green Thumb Industries (OTCMKTS:GTBIF)
Brainsway (NASDAQ: BWAY - Get Free Report) and Green Thumb Industries (OTCMKTS:GTBIF - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies base
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnin
Brainsway (BWAY) Upgraded to Buy: Here's Why
Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Receives $16.95 Average Target Price from Brokerages
Brainsway Ltd. Sponsored ADR (NASDAQ: BWAY - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven research firms that are covering the company, Marketbeat Ratings reports. One research